Adjuvant treatment of early breast cancer: Do the St Gallen recommendations influence clinical practice? Results from the NORA study

Annals of Oncology

Volumn 18, Issue 12, 2007, Pages 1976-1980

  Cazzaniga, M E ^a   Mustacchi, G ^b   Pronzato, P ^c   De matteis, A ^d   Di Costanzo, F ^e   Floriani, I ^f  

^a TREVIGLIO HOSPITAL   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; St Gallen recommendations

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GONADORELIN DERIVATIVE; HORMONE DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL PRACTICE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; EARLY CANCER; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 37349067962     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm365     Document Type: Article

References (13)

1. Breast Cancer Guidelines for Patients. Version 1.2007. American Cancer Society No. 940507. http://www.nccn.org.
2. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development conference statement: adjuvant therapy for breast cancer. J Natl Cancer Inst 2001; 93: 979-989.
3. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 2003; 21: 3357-3365.
4. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
5. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002; 20: 3317-3327.
6. Jakesz R, Hausmaninger H, Kubista E et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer. Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002; 20: 4621-4627.
7. Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002; 20: 4628-4635.
8. Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2001; 30: 67-71.
9. Henderson IC, Berry DA, Demetri GO et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
10. Mamounas EP. Evaluating the use of paclitaxel following doxorubicin/ cyclophosphamide in patents with breast cancer and positive axillary nodes. Presented at the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer, Bethesda, MD, USA, 1-3 November 2000.
11. Nabholtz J-M, Pienkowski T, Mackey J et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21: 36a (Abstr 141).
12. Cazzaniga ME, Mustacchi G, Pronzato P et al. Adjuvant systemic treatment of early breast cancer: The NORA study. Ann Oncol 2006; 17: 1386-1392.
13. Roila F, Ballatori I, Patoia L et al. Adjuvant systemic therapies in women with breast cancer, an audit at clinical practice in Italy. Ann Oncol 2003; 14: 843-848.